Introduction
============

Tissue injury triggers the rapid and transient release of soluble molecules that result in leukocyte homing to the site of injury. This process of immune cell recruitment in response to damage is termed inflammation. In an appropriate immune response, efficient pathogen elimination and the removal of antigenic material are achieved through transient non-destructive inflammation. However, antigen persistence may lead to chronic inflammation, characterized by tissue remodelling, destruction and defective healing (Ariel and Timor, [@b4]). Leukocyte motility and recruitment are at the heart of the inflammatory response. For this reason, targeting leukocyte migration constitutes an important treatment strategy for curbing immune responses. The selective modulation of immune trafficking in the treatment of pathologies has been successful in dampening excessive inflammation (autoimmunity and diseases associated with chronic inflammation; Mackay, [@b78]; Griffith and Luster, [@b43]; Di Gennaro and Haeggstrom, [@b25]) or boosting the host immune response (cancer and immune-deficiency disorders; Mellman *et al*., [@b82]; Restifo *et al*., [@b106]).

The pivotal role of immune cell migration is highlighted by the existence of many different disorders caused by defective immune cell mobilization. Immune-mediated inflammatory disorders are a heterogeneous group of diseases characterized by aberrant cytokine production and unresolved inflammation resulting from unwarranted immune responses (Williams and Meyers, [@b141]). Among these diseases are autoimmune conditions and inflammatory allergic disorders. Some examples of autoimmune diseases are autoimmune hepatitis, type I diabetes mellitus, rheumatoid arthritis (RA), Sjögren\'s syndrome, systemic lupus erythematous, multiple sclerosis (MS), psoriasis and inflammatory bowel disease (Crohn\'s disease and ulcerative colitis) (Beyaert *et al*., [@b9]). Examples of inflammatory allergic disorders include bronchial asthma, atopic dermatitis, rhinitis and food allergies. In autoimmune diseases, the immune system reacts against 'self', resulting in tissue destruction and eventual loss of function. The causes that underlie autoimmunity are still largely ignored, but there is evidence that autoimmune disorders arise as a combination of genetic makeup and unresolved inflammation (Atassi and Casali, [@b5]).

Similarly to autoimmune diseases, inflammatory allergic disorders are hyperactivity reactions. In conditions such as asthma and atopic dermatitis, however, the immune response is not directed against self, but against exogenous antigens that would be tolerated in a non-pathological context (Galli *et al*., [@b40]). Another significant inflammatory condition is the immune reaction associated with transplant allograft rejection. Unlike autoimmunity, transplant rejection is triggered by an acute challenge to an otherwise homeostatic immune system (Hautz *et al*., [@b47]). Animal models of autoimmunity, transplantation and allergic inflammation have been invaluable in the study of these complex conditions. However, the lack of understanding of what drives the chronicity of these diseases has been a considerable obstacle in translating successful treatment strategies from animal models to human disease (Feldmann and Steinman, [@b33]; Gaston, [@b42]; Beyaert *et al*., [@b9]).

One of the main strategies in the treatment of inflammatory disorders has been to impair immune cell recruitment by: (i) blocking adhesion to the endothelium and extravasation into the target tissue; (ii) modulating leukocyte influx and retention by targeting chemo-attractant receptors (Mackay, [@b78]); and (iii) curbing immune cell migration within the interstitium and target tissue (Friedl and Weigelin, [@b36]).

This review will focus on the emerging therapeutic potential of small-molecule inhibitors (SMIs) against Rho-GTPases in targeting the migratory capacity of immune cells in inflammatory disorders.

Leukocyte migration in the immune response
==========================================

Leukocytes include both innate (granulocytes, monocytes, macrophages, dendritic cells, NK cells and others) and adaptive immune cells (B and T lymphocytes). All leukocytes are generated in the bone marrow, from where they are released into the vasculature. They then leave the bloodstream for tissue surveillance and exertion of effector functions. Some leukocytes then exit organs through lymphatic venules and eventually re-enter the blood stream. The requirement for such shuttling implies that leukocytes need to move effectively in a wide variety of tissue environments and be able to penetrate the physical barriers of endothelial walls and extracellular matrices. Leukocytes are uniquely endowed with the ability to navigate almost any tissue environment in the body by virtue of their aptitude to readily switch between different migration modes to overcome tissue-specific obstructions, and likely their capacity to survive and migrate effectively without adhesion signals (Ivetic and Ridley, [@b57]; Friedl and Weigelin, [@b36]).

Leukocyte traffic from the bloodstream through the endothelium into target tissues involves a multistep process that includes: (i) tethering and rolling on the endothelial surface; (ii) crawling; (iii) firm adhesion; (iv) transmigration (diapedesis) and (v) interstitial migration (reviewed in Ley *et al*., [@b68]; Muller, [@b86]). After extravasating and traversing the interstitial space, leukocytes arrive at target sites. The ability of leukocytes to move efficiently within the extravascular compartment is fundamental to tissue surveillance and pathogen elimination. For instance, the anti-tumour activity of effector T-cells has been shown to depend on their ability to migrate and navigate effectively within the tumour (Mrass *et al*., [@b84]; [@b85]). Each step of leukocyte migration relies on a well-coordinated sequence of signalling events that exert a tight spatiotemporal regulation of cytoskeletal dynamics (Renkawitz and Sixt, [@b105]). The small GTPases of the Rho family are fundamental cytoskeletal regulators in immune cell migration (Ivetic and Ridley, [@b57]).

The cytoskeleton and Rho-GTPases in immune cell migration
=========================================================

Leukocyte migration is, as any form of animal cell migration, mediated by polarized shape changes and mechanical interactions with the extracellular environment, driven by the cytoskeleton and associated proteins. The cytoskeleton is a dynamic scaffold of protein filaments pervading the cellular cytoplasm. Not only does it confer rigidity and structure to the cell, but it is also instrumental for intracellular transport and subcellular organization. Its components are also notably responsible for driving cell movement and cell division. The cytoskeleton is composed of three different classes of protein filaments, each assembled from non-covalently bound protein monomers: microfilaments (F-actin), microtubules and intermediate filaments. The main cytoskeletal components responsible for migratory force generation are F-actin and myosin II motor proteins (collectively called actomyosin), which form a contractile and cross-linked network that subtends the plasma membrane, namely the cell cortex (Salbreux *et al*., [@b107]).

Filamentous actin
-----------------

Actin filaments have a diameter of 7--9 nm and are right-handed double-helical assemblies of parallel protofilaments, which in turn are composed of linear homopolymers of actin monomers (G-actin). G-actin is a highly conserved globular yet polar protein, consisting of four domains between which a cleft can bind to either an ATP or ADP nucleotide. The so-called nucleotide state of the actin monomer, determined by whether it is bound to an ATP or ADP, confers upon G-actin dynamic properties that affect its associative characteristics (Pollard and Cooper, [@b100]). The actin monomers are aligned in a head-to-tail fashion, endowing microfilaments with an inherent polarity, as the extremities of the filaments therefore expose opposite ends of the terminal G-actins. Actin filaments are straight and rigid, and have persistence lengths in the order of ∼15 μm (Howard, [@b55]). Aside from the nucleotide state of the available G-actin pool, the extent and ultrastructure of the polymerized actin network in a cell is dependent on nucleators (e.g. Arp2/3 complex and formins), G-actin-binding proteins (e.g. profilin), severing proteins (e.g. cofilin) and nucleation-promoting factors (NPFs) \[e.g. Scar/WAVE and Wiskott--Aldrich syndrome protein (WASp)/N-WASp\].

Myosin
------

Myosins are members of the superfamily of actin-specific molecular motors. Non-muscle myosin II (henceforth, simply myosin) is the main driving force of the cytoskeleton in immune cells, and is characterized by its ability to convert ATP hydrolysis into mechanical work. Myosin is a hexameric protein, composed of three pairs of peptides that associate to form a myosin monomer: two long heavy chains (MHC), two regulatory light chains (MRLC) and two essential light chains (ELC). Myosin ATPase activity is highly dependent on phosphorylation of MRLC, and to some extent the MHC. The main kinase responsible for myosin activation through phosphorylation is the myosin light-chain kinase (MLCK). Due to their association into anti-parallel bundles, myosins can 'walk' along actin filaments in a polarized fashion and exert forces on the F-actin network by pulling on filaments with respect to one another (Vicente-Manzanares *et al*., [@b135]).

Cytoskeletal regulation by Rho-GTPases
--------------------------------------

The forces generated by the actomyosin machinery can be either protrusive or contractile and give rise to various types of cellular protrusions that facilitate cell motility (Charras and Paluch, [@b17]; Vicente-Manzanares *et al*., [@b135]; Bergert *et al*., [@b8]). Regulation of the dynamics of the actomyosin cortex affords cells the ability to migrate using a specific method of locomotion, traditionally categorized into mesenchymal and amoeboid modes (Yoshida and Soldati, [@b147]; Keren *et al*., [@b61]). Mesenchymal migration relies on the generation of lamellipodia at the leading edge of the cell, where polymerization of filamentous actin generates protrusive forces that extend the plasma membrane into relatively stable thin sheets, and is prevalent in rigid environments that are amenable to strong adhesion. In contrast, amoeboid migration is typified by the adoption of a rounded morphology and a highly dynamic leading edge with frequent extensions and retractions of protrusions. Polarization of actomyosin dynamics is essential for the concerted propulsion of the cell in a given direction. Cellular F-actin and myosin have a myriad interaction partners that play important roles in the regulation of the actomyosin cytoskeleton. For a proper execution of convoluted processes such as immune cell locomotion, the polymerization dynamics of actin, the organization of actin networks and myosin contractility all need to be tightly regulated.

Complex and as yet incompletely mapped signalling pathways are responsible for the precise spatiotemporal regulation of cellular actomyosin. The central components of these pathways are small GTPases of the Rho family (Rho-GTPases), notably Rho, Rac and Cdc42 (Hall, [@b45]). Rho-GTPases govern both contractile and expansive forces required for cell polarization and translocation, and are intricately linked to the overarching regulation of the actomyosin cytoskeleton. Rho-GTPases are found in two inter-convertible states, namely an active GTP-bound state and an inactive GDP-bound state, and can thus function as molecular switches. Exchanges in the GTP- and GDP-state cycle are regulated by guanine nucleotide dissociation inhibitors (GDIs), GTPase-activating proteins (GAPs) and guanine nucleotide exchange factors (GEFs) (Figure [1](#fig01){ref-type="fig"}; Spiering and Hodgson, [@b115]). GDIs associate with GDP-bound GTPases and prevent these from membrane-association, in effect sequestering them in an inactive sate. GEFs catalyse GDP-to-GTP nucleotide exchange and thereby activate Rho-GTPases. GAPs promote GTP hydrolysis, leading to Rho-GTPase inactivation. In their active state, Rho-GTPases interact with over 60 different target effectors (Etienne-Manneville *et al*., [@b28]). Despite the number of potential binding partners, active Rho-GTPases interact with specific effectors at any one time. Interactions between Rho-GTPases and their effectors trigger distinct changes in the actomyosin cytoskeleton. The Rho-GTPases can mediate signalling cascades that result in actin polymerization and network formation, as well as regulate myosin contractility. A model of the intricate pathways downstream of Rho-GTPase activation and the degree of crosstalk between the different Rho-GTPases is illustrated in Figure [2](#fig02){ref-type="fig"}.

![Rho-GTPase activation and inactivation by GEFs, GAPs and GDIs. Schematic of the activation cycle of Rho-GTPases (such as Rho, Rac and Cdc42), by GEFs, GAPs and GDIs. GDIs associate with GDP-bound Rho-GTPases and sequester them in an inactive state. Dissociation of the GDI from the Rho-GTPase allows for its anchoring to the plasma membrane via a prenyl group. GEFs catalyse GDP to GTP exchange and thus activate Rho-GTPases for interaction with downstream actomyosin-regulating effectors (detailed in Figure [2](#fig02){ref-type="fig"}). GAPs stimulate the hydrolysis of GTP into GDP and phosphate (P~i~) and thereby contribute to Rho-GTPase inactivation. GDP-bound Rho-GTPases are then again sequestered by GDIs or reactivated by GEFs.](bph0171-5491-f1){#fig01}

![Regulation of cellular actomyosin dynamics by Rho-GTPases. Simplified regulatory pathway highlighting the central role of the Rho-GTPases Rho, Rac and Cdc42 in controlling actomyosin dynamics in cells. Rho and Rac inhibit one another and influence myosin contractility through effector kinases such as ROCK, PAK, Citron- and Lim kinase. MLCK phosphorylates MRLC, thereby promoting myosin activity. ROCK further inhibits myosin light-chain phosphatase, thus doubly contributing to myosin activation. Rho also activates formins, which together with G-actin-binding profilin, promotes actin polymerization. The nucleation-promoting factors Scar/WAVE and WASp/N-WASp are activated by both Rac and Cdc42, and induce actin polymerization either via Arp2/3 complex (branched actin networks) or via profilin-activation (unbranched actin networks). Rho affects actin polymerization dynamics via LIM kinase-mediated inhibition of cofilin, which as an actin-severing protein influences the balance between G- and F-actins.](bph0171-5491-f2){#fig02}

Rho (RhoA and RhoC) is mainly involved in the activation of myosin, mediated through the phosphorylation of myosin regulatory light chain (MRLC) via Rho-associated coiled-coil-forming kinase (ROCK), MLCK and Citron kinase. ROCK additionally inhibits myosin light-chain phosphatase, thus doubly contributing to myosin activation. Rho also activates the formin group of actin nucleators, responsible for rapidly polymerizing unbranched F-actin. Finally, Rho contributes to actin polymerization and the regulation of the network ultrastructure by inhibiting cofilin via LIM kinase (LIM domain kinases 1 and 2). Rac and Rho inhibit one another. Both Rac and Cdc42 activate p21-activated kinases (PAK) and thereby inhibit MLCK. Through PAK, they also activate LIM kinase, which inhibits cofilin. Rac and Cdc42 are mainly involved in the activation of both branched and unbranched actin network formation. Growth of branched actin involves Arp2/3-complex activation, mediated in the case of Rac via the NPFs Scar/WAVE, and in the case of Cdc42 via the NPFs WASp/N-WASp. The polymerization of unbranched actin is promoted via the interaction of the aforementioned NPFs with profilin and formins (Raftopoulou *et al*., [@b104]; Lee and Dominguez, [@b66]; Pertz, [@b96]).

Rho-GTPases and cell motility
-----------------------------

The selective activation of Rho-GTPases and their effectors results in the precise regulation of actin networks required to form the varying structures involved in cell motility, notably protrusions such as lamellipodia, filopodia and blebs (Pollard and Borisy, [@b99]; Charras *et al*., [@b18]). Simultaneous but spatially segregated activation of Rho-GTPases can result in the polarization of cells, such as required for sustained motility. For instance, during mesenchymal migration, cells activate Rho at the rear of the cell, thereby favouring contractile network formation. Conversely, Rac and Cdc42 are activated at the leading edge, favouring the rapid actin polymerization dynamics of lamellipodia (Burridge and Wennerberg, [@b11]). The polarized formation of Rac-dependent lamellipodia at the leading edge of motile cells is the hallmark of mesenchymal migration (Bergert *et al*., [@b8]). In contrast, RhoA- and myosin-dependent contraction of the cell rear and expansive protrusive activity at the leading edge gives rise to amoeboid motility (Lammermann and Sixt, [@b64]). Amoeboid motility is often observed in fast-moving cells such as leukocytes, which are thought to be able to undergo a blebbing migration mode (Charras and Paluch, [@b17]; Fackler and Grosse, [@b31]; Lammermann *et al*., [@b65]).

Crucially, aberrant regulation of Rho-GTPases and consequent migratory dysfunction in leukocytes has been implicated in numerous pathologies, notably inflammatory diseases (Hall, [@b45]) and cancers (Vega and Ridley, [@b132]). Because of their central role in regulating cytoskeletal dynamics and cell migration, Rho-GTPases have emerged as highly attractive pharmacological targets, particularly in inflammatory disorders where blocking tissue infiltration by leukocytes can be both prophylactic and therapeutic (Zhao and Pothoulakis, [@b150]).

Inhibiting Rho-GTPases in immune cell migration
===============================================

A precise spatiotemporal regulation of Rho-GTPases and their effectors is vital for cell migration, division, adhesion, endo- and exocytosis, polarization, as well as general cellular homeostasis. Because of their key role in such a wide variety of cellular processes, misregulation of Rho-GTPases is associated with a range of diseases characterized by aberrant cytoskeletal dynamics, notably developmental defects, immunodeficiencies and tumour metastasis (Ligeti *et al*., [@b73]). As such, Rho-GTPases and their immediate downstream effector kinases are prime targets for pharmacological modulation of the cytoskeletal dynamics of cells. By disrupting the cytoskeleton through Rho-GTPase modulation, both cell migration and tissue integrity can be influenced.

The vast majority of pharmaceutical developments targeting the cytoskeleton, and the Rho-GTPases specifically, have thus far focused on inhibiting proliferation in various malignancies. As the main regulators of the actin cytoskeleton, Rho-GTPases do in fact play pivotal roles in cell division. However, Rho-GTPases are even more prominent determinants of cell migration. Of late, efforts have, therefore, turned to curbing the migratory capacity of cancer cells, and of relevance to this review, immune cells in the context of inflammatory diseases, via inhibition of Rho-GTPases. Table [1](#tbl1){ref-type="table"} lists all the SMIs covered in the following sections.

###### 

List and status of SMIs of Rho-GTPases

  Rho-GTPase pathway         Target molecule           Name of compound                            Therapeutic status                                                                                                                                                                        Model system/pathology                                 References
  -------------------------- ------------------------- ------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Rho**                    ROCK                      Fasudil (HA-1077)                           Approved                                                                                                                                                                                  Hypertension/inflammation                              Takayasu *et al*., [@b122]; Satoh *et al*., [@b109]; Masumoto *et al*., [@b81]; Fujita *et al*., [@b38]; Ding *et al*., [@b26]; Kojonazarov *et al*., [@b62]; Li *et al*., [@b69]; Liu *et al*., [@b74]
  Dimethylfasudil (H-1152)   *In vivo*                 Hypertension models/inflammation            Sasaki *et al*., [@b108]; Warfel and D\'Agnillo, [@b140]; Breyer *et al*., [@b10]; O *et al*., [@b92]                                                                                                                                            
  Y-27632                    *In vivo*                 Hypertension/inflammation                   Uehata *et al*., [@b131]; Kawaguchi *et al*., [@b60]; Tasaka *et al*., [@b125]; Prakash *et al*., [@b102]; Schaafsma *et al*., [@b110]; Slotta *et al*., [@b114]; Chen *et al*., [@b19]                                                          
  WF-536                     *In vivo*                 Metastatic cancer models                    Nakajima *et al*., 2003a,b[@b89],[@b90]                                                                                                                                                                                                          
  Y-39983 (RKI-983)          *In vivo*                 Glaucoma                                    Tokushige *et al*., [@b128]                                                                                                                                                                                                                      
  SNJ-1656                   Phase II clinical trial   Glaucoma                                    Tanihara *et al*., [@b123]                                                                                                                                                                                                                       
  SB-772077-B                *In vivo*                 Hypertension models                         Doe *et al*., [@b27]; Dhaliwal *et al*., [@b24]                                                                                                                                                                                                  
  GSK269962A                 *In vivo*                 Hypertension models                         Doe *et al*., [@b27]                                                                                                                                                                                                                             
  K-115                      Phase II clinical trial   Glaucoma                                    Fang *et al*., [@b32]; Tanihara *et al*., [@b124]                                                                                                                                                                                                
  SR-3677                    *Ex vivo*                 Glaucoma                                    Feng *et al*., [@b34]                                                                                                                                                                                                                            
  AR-12286                   Phase II clinical trial   Glaucoma                                    Williams *et al*., [@b142]                                                                                                                                                                                                                       
  SAR407899                  Phase II clinical trial   Erectile dysfunction                        Lohn *et al*., [@b77]                                                                                                                                                                                                                            
  PT-262                     *In vitro*                Lung carcinoma cells                        Tsai *et al*., [@b129]                                                                                                                                                                                                                           
  Azaindole 1                *In vitro*                Hypertension models                         Kast *et al*., [@b59]                                                                                                                                                                                                                            
  Rho                        Rhosin                    *In vitro*                                  Breast cancer cells                                                                                                                                                                       Shang *et al*., [@b111]                                
  Y16                        *In vitro*                Breast cancer cells                         Shang *et al*., [@b112]                                                                                                                                                                                                                          
  CCG-1423                   *In vitro*                Prostate cancer cells                       Evelyn *et al*., [@b29]; [@b30]                                                                                                                                                                                                                  
  Rho/ROCK                   Rhodblocks                *In vitro*                                  Cell division Drosophila cells                                                                                                                                                            Castoreno *et al*., [@b12]                             
  Vav                        CHS-111                   *In vitro*                                  Neutrophils                                                                                                                                                                               Chang *et al*., [@b15]; [@b16]                         
  **Rac**                    Rac                       NSC23766                                    *In vitro/in vivo*                                                                                                                                                                        Prostate cancer invasion/inflammation                  Gao *et al*., [@b41]; Akbar *et al*., [@b2]; Vockel and Vestweber, [@b138]
  Rac/Cdc42                  EHop-016                  *In vitro*                                  Breast cancer cells                                                                                                                                                                       Montalvo-Ortiz *et al*., [@b83]                        
  Rac                        Compounds 7, 11           *In vitro*                                  Breast cancer cells                                                                                                                                                                       Hernandez *et al*., [@b51]                             
  EHT-1864                   *In vitro/in vivo*        Fibroblasts/Alzheimer\'s disease model      Desire *et al*., [@b23]; Shutes *et al*., [@b113]; Onesto *et al*., [@b94]                                                                                                                                                                       
  **Cdc42**                  Cdc42                     Secramine                                   *In vitro*                                                                                                                                                                                Primary smooth muscle cells/renal epithelial cells     Pelish *et al*., [@b95]; Xu *et al*., [@b143]; Lengfeld *et al*., [@b67]
  CID29950007                *In vitro*                Ovarian cancer/lymphoma cell lines          Hong *et al*., [@b54]                                                                                                                                                                                                                            
  CID44216842                *In vitro*                Ovarian cancer/lymphoma cell lines          Hong *et al*., [@b54]                                                                                                                                                                                                                            
  ZCL278                     *In vitro*                Metastatic prostate cancer cells            Friesland *et al*., [@b37]                                                                                                                                                                                                                       
  AZA1                       *In vivo*                 Prostate cancer                             Zins *et al*., [@b151]                                                                                                                                                                                                                           
  N-WASp                     187-1                     *In vitro*                                  Primary synovial isolates                                                                                                                                                                 Peterson *et al*., [@b97]; Connolly *et al*., [@b21]   
  Wiskostatin                *In vitro*                Melanoma and T-cells                        Peterson *et al*., [@b98]; Haller *et al*., [@b46]; Kovacs *et al*., [@b63]                                                                                                                                                                      
  PAK                        K252                      *In vivo*                                   Neurological disease models                                                                                                                                                               Kaneko *et al*., [@b58]                                
  KT-D606                    *In vitro*                Immortalized fibroblasts                    Nheu *et al*., [@b91]                                                                                                                                                                                                                            
  CEP-1347                   *In vitro*                Immortalized fibroblasts                    Nheu *et al*., [@b91]                                                                                                                                                                                                                            
  OSU-03012                  *In vitro*                Thyroid cancer cells                        Porchia *et al*., [@b101]                                                                                                                                                                                                                        
  IPA-3                      *In vitro*                HEK-293 cells                               Deacon *et al*., [@b22]                                                                                                                                                                                                                          
  Λ-FL172/Λ-FL411            *In vitro*                Schwannoma cancer cells                     Maksimoska *et al*., [@b79]                                                                                                                                                                                                                      
  PF-3758309                 *In vivo*                 Tumour xenograft models                     Murray *et al*., [@b87]                                                                                                                                                                                                                          
  LCH-7749944                *In vitro*                Gastric cancer cells                        Zhang *et al*., [@b148]                                                                                                                                                                                                                          
  FRAX597                    *In vivo*                 Schwannoma tumour model/neurofibromatosis   Licciulli *et al*., [@b72]                                                                                                                                                                                                                       
  **All**                    Rho/Rac/Cdc42             Berberine                                   *In vitro*                                                                                                                                                                                Nasopharyngeal cancer cells                            Tsang *et al*., [@b130]

The table summarizes the SMIs targeting Rho-GTPases discussed in this review, specifying the Rho-GTPase pathway and target molecule. The therapeutic status of the compound is indicated as either being used *in vitro*, *in vivo*, in clinical trials or as having been approved for clinical use. The model system or pathology in which the drug is being applied is given, along with pertinent references.

Rho and its kinases
===================

Notwithstanding the central role of small GTPases of the Rho family in key cellular processes and in a wide variety of pathologies, attempts to develop pharmacological agents modulating the relevant biochemical pathways have thus far been largely unproductive. This task has been found to be particularly challenging because: (i) small GTPases are generally globular in shape with limited druggable pockets exposed; (ii) the high affinity with which GTP binds to its exposed allosteric site hinders out-competition by SMIs; and (iii) the diversity and complexity of the downstream pathways governed by single Rho-GTPases make it difficult to target a specific cellular process. Thus, as the ATP-binding affinity of kinases is much lower than that of the GTP-binding affinity of RhoA, the development of SMIs against kinases such as ROCK has been much more successful (Vigil and Der, [@b136]). ROCK misregulation has been shown to significantly contribute to the pathophysiology of cancers, hypertension, glaucoma and most relevant to this review, inflammatory diseases such as asthma, diabetes, RA and MS (LoGrasso and Feng, [@b76]). Therefore, successful pharmacological treatments of inflammatory disorders have tended to target Rho kinases rather than RhoA itself.

Rho kinase (ROCK)
-----------------

A major class of SMIs targeting the pathways of Rho-GTPases are isoquinoline-based compounds. **Fasudil**, historically referred to as **HA-1077**, is the most extensively studied isoquinolinesulfonamide targeting ROCK. It was originally developed in the 1980s as an intracellular calcium ion antagonist and noted for its vasoregulatory properties in a canine model of cerebral vasospasm (Hidaka *et al*., [@b52]; Takayasu *et al*., [@b122]). It was later discovered to be an effective Ser/Thre kinase inhibitor with a wide spectrum of kinase targets, including ROCK (Uehata *et al*., [@b131]; Nagumo *et al*., [@b88]). Fasudil binds competitively to the ribose region in the ATP-binding motif of ROCK, thereby inhibiting ROCK-mediated actomyosin dynamics (Nagumo *et al*., [@b88]). Fasudil was trialled and later approved for the treatment of cerebral vasospasms (Masumoto *et al*., [@b81]; Olson, [@b93]; Suzuki *et al*., [@b120]; Velat *et al*., [@b133]), as well as pulmonary hypertension (Fukumoto *et al*., [@b39]; Ishikura *et al*., [@b56]; Fujita *et al*., [@b38]; Kojonazarov *et al*., [@b62]) in human patients. Various animal models of cancer have revealed that fasudil can block tumour invasiveness and metastasis (Ying *et al*., [@b146]). Importantly, fasudil has been successfully used to treat inflammation by interfering with leukocyte recruitment to sites of inflammation. Fasudil was shown to inhibit neutrophil infiltration in a cerebral model of infarction (Satoh *et al*., [@b109]). Furthermore, in both mouse models and human cells isolated from RA patients, fasudil treatment reduced synovial inflammation and production of pro-inflammatory cytokines (He *et al*., [@b48]). In diabetes models, fasudil decreased monocyte adhesion to endothelial cells and lowered levels of leukocyte-associated chemoattractants (Li *et al*., [@b69]). Fasudil has demonstrated anti-inflammatory effects via ROCK-mediated modification of the endothelium. It inhibited neutrophil tissue infiltration in mouse models of acute lung injury and systemic inflammation (Li *et al*., [@b71]; Ding *et al*., [@b26]). In experimental autoimmune encephalomyelitis, fasudil treatment resulted in decreased immune cell infiltration and tissue destruction, especially during disease onset (Sun *et al*., [@b118]; Liu *et al*., [@b74]). The anti-inflammatory effects of fasudil can result from either changes in endothelial permeability and modifications of cytokine production that facilitate leukocyte transmigration (Tasaka *et al*., [@b125]; Li *et al*., [@b71]), and/or from the alteration of cytoskeletal dynamics in the leukocytes themselves (Heasman *et al*., [@b49]). Fasudil-based treatments have a long history of safe clinical application with relatively mild side effects, and are thus emerging as a promising therapeutic recourse for inflammatory diseases. However, fasudil is not specific for Rho kinases and has been shown to target other kinases involved in cytoskeleton remodelling (Anastassiadis *et al*., [@b3]). This may have both beneficial effects in overcoming inherent redundancies in cytoskeletal regulation as well as adverse consequences in terms of specificity.

A derivative of fasudil, discovered in 2002, **dimethylfasudil** or **H-1152**, is a more selective inhibitor of ROCK (Sasaki *et al*., [@b108]). It has been shown to possess endothelium-modulating effects similar to those of fasudil (Breyer *et al*., [@b10]; O *et al*., [@b92]; Wang *et al*., [@b139]) and could, therefore, potentially be further developed for use in manipulating leukocyte extravasation. It was recently also suggested as a promising agent in maintaining the integrity of the endothelial barrier upon lethal anthrax toxin challenge (Warfel and D\'Agnillo, [@b140]).

**Y-27632**, an isoquinoline-based synthetic pyridine derivative, is another very extensively used ROCK inhibitor, both *in vitro* as an invaluable tool in the study of cytoskeletal regulation and in *in vivo* models of inflammatory disease. Y-27632, first developed as a potent smooth muscle relaxant to relieve hypertension, selectively targets ROCK by competitive inhibition of its ATP-binding pocket through interactions in two distinct regions (Uehata *et al*., [@b131]; Yamaguchi *et al*., [@b144]). This drug has been successfully employed in various animal models to curb leukocyte migration and reduce inflammation. In ischaemia/reperfusion and liver injury models, treatment with Y-27632 reduced inflammation, macrophage infiltration and tissue damage (Prakash *et al*., [@b102]), as well as reducing liver damage by suppressing leukocyte infiltration and inflammatory cytokines (Kawaguchi *et al*., [@b60]; Thorlacius *et al*., [@b126]; Slotta *et al*., [@b114]). Y-27632 blocked renal interstitial inflammation by dampening monocyte infiltration in chronic allograph nephropathy in rats (Liu *et al*., [@b75]). In animal models of asthma, Y-27632 inhalation resolved symptoms and reduced the number of eosinophils, macrophages and neutrophils recovered by bronchoalveolar lavage (Henry *et al*., [@b50]; Schaafsma *et al*., [@b110]). In a study of acute lung injury, Y-27632 treatment attenuated lung oedema and neutrophil infiltration of the lung parenchyma, probably as a result of ROCK-inhibition-mediated cytoskeletal rearrangement of the endothelium (Tasaka *et al*., [@b125]). Y-27632 has also successfully inhibited the invasive migration of carcinoma cells *in vitro* (Chen *et al*., [@b19]). Recently, however, Y-27632 has been reported to inhibit cytoskeleton-associated kinases other than ROCK, and this has prompted new efforts for the development of more selective ROCK inhibitors (Anastassiadis *et al*., [@b3]). Similar to fasudil, the anti-inflammatory effects of Y-27632 probably result from a combination of both endothelial modulation and migratory inhibition of immune cells.

Derivatives of Y-27632 similarly blocking ROCK-ATP binding have been developed for *in vivo* use with varying success. **WF-536** was tested as an inhibitor of invasive tumour cell migration, and was found to reduce pulmonary metastasis in metastatic mouse models without any observable associated toxicity (Nakajima *et al*., 2003a,b[@b89],[@b90]). **Y-39983**, also known as **RKI-983**, is structurally similar to Y-27632, but 30 times more potent in inhibiting ROCK activity (Tokushige *et al*., [@b128]). Topical administration of this drug in mice and monkeys resulted in lower intraocular pressure with few side effects. **SNJ-1656**, an ophthalmic solution of Y-39983, proved safe and effective in the treatment of glaucoma in human patients (Tanihara *et al*., [@b123]), and is currently in phase II clinical trials in Japan for the treatment of glaucoma, by Senju and Novartis Pharmaceuticals. These latest ROCK inhibitors show great promise for their use in treating a wider range of inflammatory disorders in the near future.

Given the promising results of the application of fasudil and Y-27632 and its derivatives in the clinic, great efforts have been invested in the discovery of other more powerful and more specific ROCK inhibitors. There has been a recent burst in the identification of different structures that are proving more potent and selective than their predecessors. Examples of these new classes of ATP-competitive ROCK inhibitors are the aminofurazan compounds, tetrahydroisoquinoline-based amides, isoquinolinesulfonamide K-115 and pyridine-thyazol compounds such as SR-3677. Aminofurazan compounds such as **SB-772077-B** and **GSK269962A**, have shown promising effects on various animal models of hypertension (Doe *et al*., [@b27]; Stavenger *et al*., [@b116]; Dhaliwal *et al*., [@b24]). Tetrahydroisoquinoline-based amides, **K-115** (Fang *et al*., [@b32]; Tanihara *et al*., [@b124]) and **SR-3677** (Feng *et al*., [@b34]), have shown encouraging results in animal models of glaucoma. In fact, K-115, from Kowa Pharmaceutical, is currently in phase II clinical trials for the treatment of glaucoma in human patients. Other ROCK inhibitors currently in clinical trials include Aerie Pharmaceuticals\' **AR-12286** (Williams *et al*., [@b142]) in phase II also for the treatment of glaucoma, and Sanofi\'s **SAR407899** (Lohn *et al*., [@b77]) in phase II for the treatment of erectile dysfunction.

Additional ROCK inhibitors in early stages of development are quinolinedione-based compounds such as the **PT-262** (Tsai *et al*., [@b129]), and **azaindole 1**, a potent orally active ROCK inhibitor that shows promise in the treatment of hypertension (Kast *et al*., [@b59]).

RhoA
----

RhoA directly influences contractile force generation via myosin-driven motor activity as well as actin polymerization kinetics.

A Rho-specific inhibitor named **rhosin**, was recently identified by rational design and virtual screening using published structures of protein : protein interactions of RhoA and its GEF leukaemia-associated RhoGEF (LARG) (Shang *et al*., [@b111]). Shang *et al*. found that rhosin specifically inhibits RhoA and RhoC interaction with GEFs. Rhosin therefore prevents RhoA activation and downstream MLC phosphorylation, filamentous actin formation and focal adhesion assembly without perturbing endogenous Cdc42 or Rac signalling. Rhosin was evaluated *in vitro* in a variety of cancer cell models, including physiological three-dimensional mammospheres, and was found to readily inhibit the motility and invasiveness of breast cancer cells in a dose-dependent manner (Shang *et al*., [@b111]). A major advantage of rhosin as a cytoskeletal inhibitor is its specificity for RhoA and RhoC, both prominent regulators of actin cytoskeleton dynamics during immune cell migration, and negligible interaction with other Rho-GTPases. However, rhosin binds RhoA with low affinity, and μM concentrations are therefore required to achieve adequate inhibition.

More recently, the same authors reported a novel compound, **Y16**, which inhibits RhoA by specifically recognizing the opposite interactive surfaces between RhoA and its GEF LARG to that of rhosin (Shang *et al*., [@b112]). Thus, Y16 and rhosin were considered amenable to being used in combination. Although Y16 treatment on its own did not show a significant improvement over rhosin in *in vitro* experiments, their combined use had a clear synergistic effect on migration, invasiveness and proliferation in a three-dimensional breast cancer model (Shang *et al*., [@b112]). Such a combined application of Y16 and rhosin provides added potency and specificity for the inhibition of RhoA activation in cells. Furthermore, it proves the efficacy of a strategy based on the rational design of combination inhibitors directly targeting Rho-GTPases, generally considered of poor 'druggability'. It will be interesting to see whether the *in vivo* combination treatment of Y16 and rhosin, or other further optimized drug pairs, is successfully applicable in inflammatory disease models.

In another approach, a phenotypic screen using cultured *Drosophila* cells pre-sensitized by partial knockdown of RhoA, identified SMIs that enhanced the knockdown phenotype (Castoreno *et al*., [@b12]). The phenotypic criterion evaluated in the screen was the ability of the cells to complete cytokinesis following treatment, which would therefore be relevant to the development of mitogenic cancer drugs. This type of phenotypic screening approach sought to uncover inhibitors of the RhoA pathway in general, including components upstream and downstream of RhoA. Eight compounds exhibited a phenotype and were collectively called **Rhodblocks**, numbered from 1 to 8. Rhodblocks 1, 3 and 6 were found to be potent inhibitors of the Rho pathway, with Rhodblock 6 determined to specifically attenuate Rho kinase activity (Castoreno *et al*., [@b12]). Although the exact mechanisms of action of these newly discovered inhibitors remain to be elucidated, they hold promise for use as cell migration modulators because of their specific inhibition of cytoskeletal regulation via the Rho pathway.

In addition to its prominent role in actin cytoskeleton regulation, RhoA is also involved with the regulation of gene transcription mediated via the serum response factor and the oncogene megakaryoblastic leukaemia 1. Evelyn and colleagues took advantage of this additional RhoA function in designing a luciferase-based high-throughput screen for specific RhoA pathway inhibitors (Evelyn *et al*., [@b29]). They identified **CCG-1423** as an inhibitor of RhoA-mediated transcription and, following compound optimization and *in vitro* Matrigel invasion experiments using prostate cancer cells, further showed its effectiveness in inhibiting invasive migration (Evelyn *et al*., [@b30]). CCG-1423 has successfully been used in mice models; however, its potential for inhibition of immune cell migration remains to be tested.

Another prospective modulator of immune cell migration via RhoA activity-inhibition is **CHS-111**, a novel compound described in Chang *et al*. ([@b15]). CHS-111 was subsequently found to reduce levels of active GTP-bound RhoA by blocking the activation of the RhoA-specific GEF Vav. Consequently, CHS-111 impedes the recruitment of RhoA and ROCK to the plasma membrane and limits the phosphorylation of myosin light chain 2, as shown in stimulated rat neutrophils (Chang *et al*., [@b16]). CHS-111 inhibits neutrophil migration in a dose-dependent manner without affecting degranulation. It should be noted that CHS-111 was also found to inhibit Rac2 activation in stimulated neutrophils (Chang *et al*., [@b15]), which might help overcome the inherent redundancies in cytoskeletal regulation and may, therefore, prove especially efficacious in curbing leukocyte migration. However, such lack of specificity could also lead to undesired effects. *In vivo* testing of this new compound is still outstanding.

Rac
===

Rac GTPases are pleiotropic modulators of a variety of important cellular processes, including actin polymerization dynamics and the formation of migratory protrusions such as lamellipodia. Rac regulates actin polymerization through PAK- and LIM kinase-mediated inhibition of cofilin, as well as through Arp2/3 complex branched actin nucleation. Misregulation of Rac activity has been implicated in various pathologies, including invasive cancers and immunodeficiency.

**NSC23766**, a first generation of Rac-specific SMI, was identified in a computer-based virtual screen and was found to inhibit Rac activity by blocking Rac-GTP loading without affecting RhoA or Cdc42 (Gao *et al*., [@b41]). It was later established that NSC23766 prevented GEF-mediated activation (Akbar *et al*., [@b2]). In both *in vitro* and *in vivo* systems, it was shown that NSC23766 inhibited tumour cell transformation and invasion, lamellipodia formation and haematopoietic progenitor cell mobilization (Gao *et al*., [@b41]; Akbar *et al*., [@b2]). NSC23766 also inhibited platelet aggregation (Akbar *et al*., [@b2]). In an *in vitro* system, Vockel and Vestweber showed that adhesion of leukocytes to the endothelium triggers a signalling cascade that involves Rac1 activation for the dissociation of intercellular junctions within the endothelium (Vockel and Vestweber, [@b138]). Such endothelial 'loosening' facilitates efficient leukocyte transmigration, which is blocked by NSC23766. It will be interesting to see the outcome of the application of this novel drug in animal models of inflammatory disease.

A derivative of NSC23766, **EHop-016**, is a more potent and more effective SMI than its parent compound. It inhibits Rac1 and Rac3, but also Cdc42 by preventing GEF-mediated activation by competitive binding. EHop-016 specifically interferes with the interaction between Rac and its GEF Vav. *In vitro* EHop-016 treatment inhibited lamellipodia formation and directed migration in invasive metastatic breast cancer cells (Montalvo-Ortiz *et al*., [@b83]). Also related to NSC23766, **Compounds 7** and **11** were generated by molecular docking,and were found to be two to three times more potent than NSC23766 (Hernandez *et al*., [@b51]). Similar to the related EHop-016, these compounds inhibited cell spreading and lamellipodia formation in metastatic breast cancer cells with no observable effect on normal epithelial cells. Importantly, the cytoskeletal alterations caused by these compounds were more dramatic than those observed in the presence of NSC23766 (Hernandez *et al*., [@b51]). Molecular docking and virtual screening also lead to the discovery of five new SMIs against Rac1 (as yet unnamed; Ferri *et al*., [@b35]). These compounds proved significantly more effective than the reference compound NSC23766 in inhibiting Rac1 and resulted in a very similar cytoskeletal phenotype.

Another interesting SMI, **EHT-1864** (Desire *et al*., [@b23]) binds tightly to Rac1 (also to Rac2 and to a lesser extent Rac3) by blocking it in an inactive state, and thus inhibiting inherent Rac-mediated cytoskeletal changes. EHT-1864 was effective in reducing plaque formation and associated neuronal toxicity in a guinea pig model of Alzheimer\'s disease (Desire *et al*., [@b23]). Treatment of NIH-3T3 cells with EHT-1864, resulted in inhibition of Rac1-dependent lamellipodia formation and cellular transformation *in vitro* (Shutes *et al*., [@b113]; Onesto *et al*., [@b94]).

The evidently successful Rac-dependent inhibition of cytoskeletal rearrangements in a wide variety of cell types, including immune cells, highlights the potential therapeutic value of SMIs against Rac GTPases in the treatment of immune diseases.

Cdc42
=====

The Rho-GTPase Cdc42 is one of the main cytoskeletal modulators. Cdc42 participates in a variety of cytoskeletal processes such as polarity establishment, migration, adhesion, membrane ruffling and intracellular trafficking (Cerione, [@b13]). Cdc42 is required for the formation of lamellipodia and filopodia. These cell protrusions are central to certain migration modes and are formed, via WASp, by Arp2/3 and formin-nucleated actin networks. Cdc42 is associated with carcinogenesis and metastasis, hence significant effort has been invested in the development of SMI targeting the Cdc42 signalling pathway. Defects in Cdc42 signalling are associated with various human diseases including neurodegenerative conditions (Auer *et al*., [@b6]), cancer and metastasis, and genetic disorders such as Fanconi anaemia (Stengel and Zheng, [@b117]). Notably, Fanconi anaemia is characterized by a variety of haematological abnormalities including defects in adhesion and homing of haematopoietic progenitors, a feature attributed, at least in part, to Cdc42 dysfunction (Zhang *et al*., [@b149]).

The first selective inhibitor of Cdc42 discovered was **secramine**. An analogue of the natural product galanthamine, it was found by high-throughput phenotypic screening for molecules that interfered with membrane trafficking (Pelish *et al*., [@b95]). Secramine prevents the activation and membrane availability of Cdc42 by stabilizing its interaction with GDIs. *In vitro* experiments revealed secramine to inhibit cell spreading (Xu *et al*., [@b143]) and to interfere with Golgi polarization during migration in a wound-healing assay (Pelish *et al*., [@b95]). Treatment of mouse primary smooth muscle cells with secramine inhibited secretion of collagen, suggesting that Cdc42 inhibition could be useful in the treatment of atherosclerotic plaque formation in cardiovascular diseases (Lengfeld *et al*., [@b67]). In platelets, secramine reduced integrin-mediated adhesion to collagen (Pula and Poole, [@b103]). **CID29950007** (also **ML141**) and its related analogue **CID44216842** are novel SMIs of Cdc42 that act by blocking nucleotide binding with no effect on RhoA or Rac (Surviladze *et al*., [@b119]; Hong *et al*., [@b54]). These compounds inhibited migration and filopodia formation in cultured fibroblasts, and chemotaxis in ovarian cancer cells. Importantly, in an *in vitro* model of leukocyte adhesion, CID29950007 blocked integrin binding to its endothelial receptor (vascular cell adhesion molecule 1) (Hong *et al*., [@b54]), suggesting the potential usefulness of this compound in immune cell trafficking. **ZCL278**, another novel selective SMI of Cdc42, was discovered by virtual screening and found to inhibit Cdc42 activity by directly blocking GEF binding (Friesland *et al*., [@b37]). This compound was tested in a variety of *in vitro* models and was shown to inhibit migration in prostate cancer cells and filopodia formation in fibroblasts and primary neurons (Friesland *et al*., [@b37]). A derivative of NSC23766, **AZA1** was identified by virtual screening and found to inhibit Cdc42 as well as Rac1 by blocking GEF binding (Zins *et al*., [@b151]). *In vitro* use of AZA1 resulted in altered cytoskeletal dynamics, reduced migration, lamellipodia and filopodia formation in prostate cancer cells, while *in vivo* administration decreased tumour growth and increased survival in a mouse xenograft model of prostate cancer (Zins *et al*., [@b151]). Given that most of the Cdc42 inhibitors mentioned earlier act upon different molecular targets and via differing mechanisms, it will be interesting to see whether they are amenable to safe use in combination and whether therapeutic potency can thereby be increased. **Berberine**, a natural isoquinoline alkaloid, is an inhibitor of all three Rho-GTPases. Its active ingredient, Coptidis rhizome, was traditionally used in Chinese medicine. In *in vitro* studies using various cancer cell types, low doses of berberine treatment inhibited migration and invasion, while higher doses resulted in mitotic arrest (Tsang *et al*., [@b130]).

Wiskott--Aldrich syndrome proteins
----------------------------------

In an attempt to develop novel pathway inhibitors, efforts have also been focused on targeting direct downstream effectors of Cdc42 such as WASp, including the ubiquitously expressed N-WASp. WAS family proteins are key NPFs of the Arp2/3 complex. WASp can bind both the Arp2/3 complex and actin monomers and have two crucial stimulating roles in Arp2/3-driven actin polymerization within cells (Pollard and Cooper, [@b100]). On the one hand, WASp induce activation of conformational changes in the Arp2/3 complex itself, on the other hand, WASp help recruit, via intermediary binding, actin monomers to the Arp2/3 complex (Chesarone and Goode, [@b20]). Importantly, haematopoietic WASp, is a key multifunctional cytoskeletal regulator in immune cells with roles in immune-target cell interactions, apoptosis, signalling and leukocyte migration. The significance of this NPF in immunity is illustrated by its name WASp, from its involvement in Wiskott--Aldrich syndrome, a group of immunological disorders caused by inactivating mutations in the *WASP* gene and characterized by increased susceptibility to infections, eczema and thrombocytopoenia (Thrasher and Burns, [@b127]).

The N-WASp inhibitor **187-1** is a synthetic 14-residue cyclodimeric peptide identified in a high-throughput screen of xenopus cell-free extracts aimed to identify novel inhibitors of actin polymerization (Peterson *et al*., [@b97]). 187-1 inhibits N-WASp by locking it in its auto-inhibited conformation. *In vitro* experiments using synovial tissue from patients with RA showed that treatment with 187-1 resulted in altered cytoskeletal rearrangements accompanied by reduced cellular migration and invasion (Connolly *et al*., [@b21]). A few years later, using an identical procedure, Peterson and collaborators discovered **wiskostatin**, another N-WASp inhibitor that similarly prevents the activation of the Arp2/3 complex by stabilizing N-WASp activity in its inactive state (Peterson *et al*., [@b98]). Treatment with this drug decreased membrane ruffling in melanoma cells (Kovacs *et al*., [@b63]) and blocked T-cell activation in cultured lymphocyte lines (Haller *et al*., [@b46]). However, in another study, wiskostatin was shown to interfere with energy stores, protein synthesis and processing, cellular processes unlikely to be mediated by N-WASp (Guerriero and Weisz, [@b44]). Such an unwarranted effect cautions against the use of wiskostatin as a specific N-WASp inhibitor in *in vivo* models.

P21-activated kinases
---------------------

PAK are downstream effectors of both Cdc42 and Rac GTPases. PAKs are involved in cell cycle progression and proliferation; however, they are best known for their role in cell polarity and plasticity, through modulation of the actin cytoskeleton. Some of the cytoskeletal effects of PAK activation include cell elongation, and loss of focal adhesions and stress fibres (Manser *et al*., [@b80]). PAKs are also involved in the modulation of endosomal membrane transport, membrane ruffling, filopodia and lamellipodia formation (Szczepanowska, [@b121]). PAK signalling deregulation is associated with tumourigenesis and cancer progression, neurodegenerative diseases and infection (Chan and Manser, [@b14]). There are two types or PAKs. Group I PAKs PAK1, PAK2 and PAK3 are directly activated via interaction with Rac and Cdc42, while group II PAKs (4 to 6) do not directly interact with Rho-GTPases (Chan and Manser, [@b14]). The role of PAK as an important effector of Rho-GTPases and their role in cytoskeletal modulation and cell cycle progression have made them attractive targets for drug discovery.

**Staurosporine** and its relative **K252**, are natural, potent broad spectrum kinase inhibitors that act by competitively binding to the allosteric ATP site of their target (Kaneko *et al*., [@b58]; Yi *et al*., [@b145]). **KT-D606** and **CEP-1347**, derived from K252, are more selective than their predecessors, and effectively suppress H-Ras-mediated transformation in immortalized fibroblasts. KT-D606 and CEP-1347, however, inhibit both PAK and MLK3 kinases, and are not potent enough to be effective *in vivo* (Nheu *et al*., [@b91]). **OSU-03012** is another ATP-competitive inhibitor of PAK. It was originally derived from the COX inhibitor celocoxib as a PDK1 antagonist, but was later rediscovered as an even more potent suppressor of PAK activity (Porchia *et al*., [@b101]). *In vitro* treatment of thyroid cancer cells with OSU-03012 resulted in reduced proliferation and migration (Porchia *et al*., [@b101]). **IPA-3** is a more selective inhibitor of the PAKs (Deacon *et al*., [@b22]). This compound binds the regulatory domain of PAK, stabilizing the kinase in its auto-inhibited conformation (Deacon *et al*., [@b22]). However, IPA-3 is unstable under physiological conditions and is unlikely to be effective *in vivo* (Viaud and Peterson, [@b134]). Two other preferential inhibitors of PAK1, Λ-**FL172** and Λ-**FL411**, were generated by modifying other compounds with bulky ruthenium-scaffolds to selectively target the wide ATP-binding groove of PAK1 (Maksimoska *et al*., [@b79]). Λ-FL172 was highly selective for group I PAKs and effective at sub-micromolar concentrations *in vitro*. These compounds are currently under development for *in vivo* use (Maksimoska *et al*., [@b79]). **PF-3758309** was identified using high-throughput screening of structure-based SMI libraries (Murray *et al*., [@b87]). PF-3758309, a pyrrolo--pyrazole compound, is a potent ATP-competitive inhibitor of PAK. It effectively blocks the activity of PAK1, PAK4, PAK5 and PAK6, and is less potent against the remaining PAK2 and PAK3. PF-3758309 was tested in a variety of xenograft cancer models and was shown to effectively block tumour growth (Murray *et al*., [@b87]). More recently, another ATP-competitive inhibitor of PAK4 was discovered, **LCH-7749944** (with lower potencies against PAK1, PAK5 and PAK6). *In vitro* treatment of invasive gastric cancer cells with LCH-7749944 resulted in reduced proliferation, filopodia formation, migration and invasion (Zhang *et al*., [@b148]). The latest addition to the list is the pyridopyrimidinone **FRAX597**. FRAX597 was identified by high-throughput screening as a potent ATP-competitive inhibitor of group I PAKs (Licciulli *et al*., [@b72]). FRAX597 was shown to decrease proliferation in cultured Schwannoma cells and reduce tumour development in an orthotropic model of neurofibromatosis (Licciulli *et al*., [@b72]). The majority of these compounds have been developed as potential cancer treatments and are still in their infancies. However, three of the compounds (PF-3758309, LCH-7749944 and FRAX597) have already shown beneficial effects on animal cancer models, suggesting therapeutic promise. It will be interesting to see the development of SMIs targeting PAK in the clinic and their potential application to other diseases, particularly inflammatory diseases.

Prenyltransferases
------------------

Another relevant strategy to block small Rho-GTPase activity is through inhibition of protein prenylation, a post-translational modification that consists in the addition of hydrophobic moieties. The transfer of farnesyl or geranylgeranyl modifications onto Rho-GTPases by prenyltransferases is required for membrane recruitment and substrate activation. A vast number of compounds against prenyltransferases have been developed and more than 70 clinical cancer trials have been performed so far with disappointing results.

Prenylation is responsible for membrane-targeting of Rho-GTPases, whereas this review focuses on the inhibition of the interaction of Rho-GTPases and their downstream effectors; we shall, therefore, not cover this set of drugs in further detail. These groups of compounds and their clinical applications have been extensively reviewed elsewhere (Basso *et al*., [@b7]; Holstein and Hohl, [@b53]; Li *et al*., [@b70]).

Concluding remarks
==================

Because of their central role in actin cytoskeleton regulation, targeting the Rho family of small GTPases, and their immediate downstream effectors, is a promising strategy for curbing the migration of leukocytes. Pharmacological inhibition of immune cell motility can be highly beneficial in a vast number of inflammatory disorders where excessive tissue infiltration can cause significant damage. The lack of effective and selective therapies for such diseases has failed to resolve their chronicity and consequently required the continued use of immune-suppressive treatments, such as corticosteroids, with potential side effects. Advances in drug design technologies and high-throughput experimental assays have brought about a novel class of highly specific SMIs that have proven their worth in the laboratory. Precise characterizations, dose optimizations and the production of improved derivatives are now leading to successful applications of drugs that target Rho-GTPase in animal models, and clinical trials. The application of SMIs for inhibiting Rho-GTPases is particularly attractive in the context of immune cell migration in inflammatory disease, because of the potential for developing leukocyte- or migration mode-specific drugs. The directed inhibition of a particular Rho-GTPase regulatory pathway can lead to the complete inhibition of specific cytoskeletal dynamics, thus potentially allowing for both potency and specificity. Rho-GTPase-targeted cytoskeletal modulation can lead to changes in endothelial cohesion or the cell-intrinsic capacity for leukocyte motility and can, therefore, be adapted to suit the pathophysiology of particular inflammatory diseases. The use of combination treatments of SMIs targeting Rho-GTPases is an interesting prospect currently being tested.

A key consideration for the future is the development of inhibitors that target a specific subset of leukocytes without diminishing the capacity of other subsets to perform their immunodefensive roles. The general inhibition of leukocyte trafficking results in the host being more susceptible to infections and having a diminished capacity for the homeostatic immuno-surveillance of tissues, which could potentially lead to oncogenic events being left unchecked. However, higher numbers of macrophages, mast cells and neutrophils detected within the tumour environment correlate with a poorer prognosis, whereas a greater infiltration of the tumour by lymphocytes correlates with a favourable prognosis (de Visser *et al*., [@b137]). Furthermore, chronic inflammation increases the risk of carcinogenesis. It, therefore, remains to be established to what extent the benefits of inhibiting leukocyte migration in an inflammatory context outweigh the long-term effects on the risk of developing cancer.

The recent developments discussed in this review are yet to be fully translated into clinical applications, and the next few years will surely see the emergence of eagerly awaited effective treatments for a set of conditions experiencing a steep rise in global incidence.

M. B. is supported by the Sydney Medical School at The University of Sydney and the Cure Cancer Australia Foundation. M. B. and W. W. are supported by fellowships from the Cancer Institute New South Wales. W. W. is supported by the Australian National Health and Medical Research Council and the Australian Research Council.

Conflict of interest
====================

The authors have no conflict of interest to declare.

GAP

:   GTPase-activating protein

GDI

:   guanine nucleotide dissociation inhibitor

GEF

:   guanine nucleotide exchange factor

NPF

:   nucleation-promoting factor

SMI

:   small-molecule inhibitor
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